{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:34:27Z","timestamp":1785270867517,"version":"3.55.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>This review provides an overview of the management of chronic kidney disease (CKD) associated with type 2 diabetes (T2D), how the novel treatment class of nonsteroidal mineralocorticoid receptor antagonists (MRAs) fits within the treatment landscape, and how pharmacists can contribute to the multidisciplinary care of patients with CKD associated with T2D.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Optimizing pharmacotherapy for patients with CKD associated with T2D is critical to prevent or slow progression to end-stage kidney disease and reduce the incidence of cardiovascular events. However, many patients with CKD receive suboptimal treatment, in part because of the high complexity of care required, a lack of disease recognition among providers and patients, and a failure to utilize new kidney-protective therapies. Finerenone is the first nonsteroidal, selective MRA to be approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of adult patients with CKD associated with T2D. Clinical trials have demonstrated that finerenone significantly reduces the risk of cardiorenal disease progression vs placebo and has a reduced risk of hyperkalemia compared to traditional steroidal MRAs. Initiation of finerenone should follow evaluation of baseline estimated glomerular filtration rate and serum potassium levels. Consideration of potential drug-drug interactions, follow-up monitoring of potassium levels, and coordination of changes in pharmacotherapy across the patient care team are also important.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Finerenone is a valuable addition to the treatment landscape for CKD associated with T2D. Through their expertise in \u00admedication \u00admanagement, transitions of care, and patient education, clinical pharmacists are well positioned to ensure patients receive safe and effective \u00adtreatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxad192","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:22:19Z","timestamp":1692973339000},"page":"1708-1721","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes"],"prefix":"10.1093","volume":"80","author":[{"given":"Emily","family":"Ashjian","sequence":"first","affiliation":[{"name":"Pharmacy Innovations & Partnerships, Michigan Medicine , Ann Arbor, MI"},{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Clarke","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Medical Center , Chapel Hill, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Pogue","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, MI"},{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"issue":"10225","key":"2023112211560461500_CIT0001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2023112211560461500_CIT0002","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2023112211560461500_CIT0003","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2023112211560461500_CIT0004","volume-title":"2021 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States","author":"US Renal Data System","year":"2021"},{"issue":"5","key":"2023112211560461500_CIT0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2023112211560461500_CIT0006","doi-asserted-by":"crossref","first-page":"e000154","DOI":"10.1136\/bmjdrc-2015-000154","article-title":"Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns\u2014NHANES 2007\u20132012","volume":"4","author":"Wu","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"17","key":"2023112211560461500_CIT0007","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"2023112211560461500_CIT0008","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/00325481.2021.2009726","article-title":"Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations","volume":"134","author":"Shubrook","year":"2022","journal-title":"Postgrad Med"},{"issue":"7","key":"2023112211560461500_CIT0009","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jac5.1309","article-title":"Nephrology practice and research network opinion paper: pharmacists\u2019 perspectives on the Advancing American Kidney Health initiative","volume":"3","author":"Meaney","year":"2020","journal-title":"J Am Coll Clin Pharm"},{"issue":"3","key":"2023112211560461500_CIT0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s11096-019-00816-4","article-title":"Clinical pharmacy practice in the care of chronic kidney disease patients: a systematic review","volume":"41","author":"Al Raiisi","year":"2019","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"2023112211560461500_CIT0011","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/MNH.0b013e328365b364","article-title":"New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication management","volume":"22","author":"St Peter","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"2023112211560461500_CIT0012","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1053\/j.ackd.2021.02.001","article-title":"Overcoming barriers to implementing new therapies for diabetic kidney disease: lessons learned","volume":"28","author":"Neumiller","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"13","key":"2023112211560461500_CIT0013","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2023112211560461500_CIT0014","year":"2021"},{"issue":"5","key":"2023112211560461500_CIT0015","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"issue":"12","key":"2023112211560461500_CIT0016","doi-asserted-by":"crossref","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2023112211560461500_CIT0017","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular disease and risk management: Standards of Care in Diabetes","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2023112211560461500_CIT0018","year":"2020"},{"key":"2023112211560461500_CIT0019","year":"2022"},{"issue":"6","key":"2023112211560461500_CIT0020","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"2023112211560461500_CIT0021","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"2023112211560461500_CIT0022","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2023112211560461500_CIT0023","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"2023112211560461500_CIT0024","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"2023112211560461500_CIT0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2023112211560461500_CIT0026","doi-asserted-by":"crossref","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"issue":"2","key":"2023112211560461500_CIT0027","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"31","key":"2023112211560461500_CIT0028","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"27","key":"2023112211560461500_CIT0029","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"2023112211560461500_CIT0030","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"2023112211560461500_CIT0031","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"2023112211560461500_CIT0032","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023112211560461500_CIT0033","author":"Bayer"},{"issue":"4","key":"2023112211560461500_CIT0034","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2023112211560461500_CIT0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2023112211560461500_CIT0036","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","article-title":"Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo","volume":"43","author":"Heinig","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"2023112211560461500_CIT0037","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone \u2013 results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"2023112211560461500_CIT0038","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with mild or moderate hepatic impairment","volume":"44","author":"Heinig","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"2023112211560461500_CIT0039","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical management of hyperkalemia","volume":"96","author":"Palmer","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2023112211560461500_CIT0040","doi-asserted-by":"crossref","first-page":"R135","DOI":"10.1530\/EC-18-0109","article-title":"a clinical update","volume":"7","author":"Kardalas","year":"2018","journal-title":"Endocr Connect"},{"issue":"6","key":"2023112211560461500_CIT0041","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1053\/j.ajkd.2017.09.003","article-title":"Potassium homeostasis in health and disease: a scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension","volume":"70","author":"Kovesdy","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"24","key":"2023112211560461500_CIT0042","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"issue":"6","key":"2023112211560461500_CIT0043","first-page":"CD013165","article-title":"Potassium binders for chronic hyperkalaemia in people with chronic kidney disease","volume":"6","author":"Natale","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2023112211560461500_CIT0044","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/ndt\/gfz206","article-title":"Hyperkalemia: pathophysiology, risk factors and consequences","volume":"34","author":"Hunter","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2023112211560461500_CIT0045","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2020.03.023","article-title":"NSAIDs in CKD: are they safe","volume":"76","author":"Baker","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2023112211560461500_CIT0046","doi-asserted-by":"crossref","first-page":"A508","DOI":"10.1016\/j.jval.2015.09.1458","article-title":"Patient benefits and cost savings predicted for mineralocorticoid-receptor antagonist treatment of early and advanced diabetic kidney disease","volume":"18","author":"Blankenburg","year":"2015","journal-title":"Value Health"},{"key":"2023112211560461500_CIT0047","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.37765\/ajmc.2021.88808","article-title":"FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes","volume":"27","author":"Pochopien\u0301","year":"2021","journal-title":"Am J Manag Care"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxad192\/51551121\/zxad192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/23\/1708\/53678076\/zxad192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/23\/1708\/53678076\/zxad192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:26:16Z","timestamp":1700673976000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/23\/1708\/7252071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":47,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,8,26]]},"published-print":{"date-parts":[[2023,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxad192","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,8,26]]}}}